Hypokalaemia in healthy volunteers after single and multiple doses of formoterol or salbutamol

Clinical Drug Investigation

Volumn 15, Issue 6, 1998, Pages 523-529

  Van Den Berg, B T J ^a   Louwerse, R T ^a   Luiken, G J H M ^a   Jonkers, R E ^a   Van Boxtel, C J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FORMOTEROL; POTASSIUM ION; SALBUTAMOL;

AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HUMAN EXPERIMENT; HYPOKALEMIA; INHALATIONAL DRUG ADMINISTRATION; MALE; METHODOLOGY; NORMAL HUMAN; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; TACHYPHYLAXIS;

EID: 0031834205     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199815060-00009     Document Type: Article

References (36)

1. Ramsdale EH, Otis J, Kline PA, et al. Prolonged protection against methacholine-induced bronchoconstriction by the inhaled beta 2-agonist formoterol. Am Rev Respir Dis 1991; 143: 998-1001
2. van den Berg BTJ, Smeets JJ, van Boxtel CJ, et al. Evaluation of different doses of formoterol from a newly developed powder inhalation device in asthmatic patients. Fundam Clin Pharmacol 1995; 9: 593-603
3. Stam J, Souren M, Zweers PG. The onset of action of formoterol, a new beta 2 adrenoceptor agonist. Int J Clin Pharmacol Ther Toxicol 1993; 31: 23-6
4. Derom EY, Pauwels RA. Time course of bronchodilating effect of inhaled formoterol, a potent and long acting sympathomimetic. Thorax 1992; 47: 30-3
5. Chetta A, Del Donno M, Maiocchi G, et al. Prolonged bronchodilating effect of formoterol versus procaterol in bronchial asthma. Ann Allergy 1993; 70: 171-4
6. Malo JL, Cartier A, Trudeau C, et al. Formoterol, a new inhaled beta-2 adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction. Am Rev Respir Dis 1990; 142: 1147-52
7. McAlpine LG, Thomson NC. Prophylaxis of exercise-induced asthma with inhaled formoterol, a long-acting beta 2-adrenergic agonist. Respir Med 1990; 84: 293-5
8. Nix A, Nichol GM, Robson A, et al. Effect of formoterol, a long-lasting beta 2-adrenoceptor agonist, against methacholine-induced bronchoconstriction. Br J Clin Pharmacol 1990; 29: 321-4
9. Hekking PR, Maesen FP, Greefhorst A, et al. Long-term use of formoterol fumarate. Lung 1990; 168 Suppl.: 76-82
10. Kesten S, Chapman KR, Broder I, et al. Sustained improvement in asthma with long-term use of formoterol fumarate. Ann Allergy 1992; 69: 415-20
11. Maesen FP, Costongs R, Smeets JJ, et al. The effect of maximal doses of formoterol and salbutamol from a metered dose inhaler on pulse rates. ECG and serum potassium concentrations. Chest 1991; 99: 1367-73
12. Haalboom JRE, Deenstra M, Struyvenberg A. Hypokalemia induced by inhalation of fenoterol. Lancet 1985; 1: 1125-7
13. Kung M, White JR, Burki NK. The effect of subcutaneously administered terbutaline on serum potassium in asymptomatic adult asthmatics. Am Rev Respir Dis 1983; 129: 329-32
14. Neville A, Palmer JBD, Gaddie J, et al. Metabolic effect of salbutamol: comparison of aerosol intravenous administration. BMJ 1977; 1: 413-4
15. Clausen T, Flatman JA. Beta 2-adrenoceptors mediate the stimulating effect of adrenaline on active electrogenic Na-K transport in rat soleus muscle. Br J Pharmacol 1980; 68: 749-55
16. Brown MJ, Brown DC, Murphy MB. Hypokalemia from beta2-receptor stimulation by circulating epinephrine. N Engl J Med 1983; 309: 1414-9
17. Struthers AD, Reid JL, Whitesmith R, et al. Effect of intravenous epinephrine on electrocardiogram, blood pressure and serum potassium. Br Heart J 1983; 49: 90-3
18. Jonkers RH, van Boxtel CJ, Oosterhuis B. Beta 2 adrenoceptor mediated hypokalemia and its abolishment by oxprenolol. Clin Pharmacol Ther 1987; 42: 627-33
19. Jonkers RE, van Boxtel CJ, Koopmans RP, et al. A non-steady state agonist antagonist interaction model using plasma potassium concentrations to quantify the beta-2 selectivity of beta-blockers. J Pharmacol Exp Ther 1989; 249: 297-302
20. Jonkers RE, Koopmans RP, Portier EJG, et al. Debrisoquine phenotype and the pharmacokinetics and β2-adrenoceptor pharmacodynamics of metoprolol and its enantiomers. J Pharmacol Exp Ther 1991; 256: 954-66
21. Braat MCP, Jonkers RE, van Boxtel CJ. Quantification of metoprolol beta 2-adrenoceptor antagonism in asthmatic patients by pharmacokinetic-pharmacodynamic modelling. Pulmon Pharmacol 1992; 5: 31-8
22. Lofdahl CG, Svedmyr N. Formoterol fumarate, a new beta 2-adrenoceptor agonist. Acute studies of selectivity and duration of effect after inhaled and oral administration. Allergy 1989; 44: 264-71
23. Faulds D, Hollingshead LM, Goa KL. Formoterol. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Drugs 1991; 42: 115-37
24. Lemoine H, Overlack C. Highly potent beta-2 sympathomimetics convert to less potent partial agonists as relaxants of guinea pig tracheae maximally contracted by carbachol. Comparison of relaxation with receptor binding and adenylate cyclase stimulation. J Pharmacol Exp Ther 1992; 261: 258-70
25. Zanotti A, Mariot R, Contarino A, et al. Lack of anticonvulsant tolerance and benzodiazepine receptor downregulation with imidazenil in rats. Br J Pharmacol 1996; 117: 647-52
26. Vela-Bueno A, Kales A, Benzodiazepine hypnotics in the multidimensional treatment of insomnia. Drugs Today 1986; 22: 271-81
27. Vegontzas AN, Kales A, Bixler EO. Benzodiazepine side effects: role of pharmacokinetics and pharmacodynamics [review]. Pharmacology 1995; 51: 205-23
28. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker, 1984
29. Scheinin M, Koulu M, Laurikainen E, et al. Hypokalaemia and other non-bronchial effects of inhaled fenoterol and salbutamol: a placebo-controlled dose-response study in healthy volunteers. Br J Clin Pharmacol 1987; 24: 645-53
30. Tattersfield AE. Clinical pharmacology of long-acting beta-receptor agonists. Life Sci 1993; 52: 2161-9
31. Kesten S, Chapman KR, Broder I, et al. Sustained improvement in asthma with long-term use of formoterol fumarate. Ann Allergy 1992; 69: 415-20
32. Chrystyn H. Standards for bioequivalence of inhaled products [review]. Clin Pharmacokinet 1994; 26: 1-6
33. Davies DS. The fate of inhaled terbutaline. Eur J Respir Dis 1984; 65 Suppl. 134; 141-8
34. Lipworth BJ, Struthers AD, McDevitt DG. Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high dose inhaled salbutamol in asthmatics. Am Rev Respir Dis 1989; 140: 586-92
35. Kompa AR, Molenaar P, Summers RJ. Beta-adrenoceptor regulation and functional responses in the guinea-pig following chronic administration of the long-acting beta2-adrenoceptor agonist formoterol. Naunyn Schmiedebergs Arch Pharmacol 1995; 351: 576-88
36. Yates DH, Sussman HS, Shaw MJ, et al. Regular formoterol treatment in mild asthma. Effect on bronchial responsiveness during and after treatment. Am J Respir Care Med 1995; 152: 1170-4